Among biologic therapies, a wide range of immunogenicity rates have been reported, from < 1% to > 50% in some cases [
11]. The immunogenicity of biologic therapies is influenced by a range of factors, including product-specific or treatment-related factors (eg, dose, route of administration, protein structure, protein stability, and formulation) and patient-related factors (eg, genetic predisposition, age, disease status, concomitant medication use, comorbidities) [
10‐
12,
15]. Both the type and magnitude of ADAs produced can vary greatly between individuals, further affecting the extent to which ADAs impact each patient. Finally, ADA binding to a target therapeutic protein can lead to the formation of immune complexes that may significantly impact the extent to which ADAs and NAbs affect a given treatment [
13]. It has been suggested that therapies administered by subcutaneous injection are more immunogenic than those administered intravenously, and this is thought to be related to the presence of cutaneous dendritic cells serving as APCs leading to T cell–dependent ADA production [
11]. Therapeutic proteins containing human or fully humanized sequences tend to be less immunogenic than those containing murine or chimeric sequences; moreover, proteins with a high likelihood of forming immune complexes, containing epitopes recognized by class II MHC, and/or certain posttranslational modifications (eg, glycosylation) are more immunogenic than those lacking these elements [
11,
12]. Due to a significant impact of peptide sequence on immunogenicity, a range of in silico and in vitro tools exist to identify and minimize risk when developing a biologic therapy. Biologic therapies can be evaluated to determine the risk of immunogenicity by identifying potential T cell epitopes using in silico analyses (eg, statistical, interference, or structural modeling) or in vitro T cell stimulation [
16]. This approach provides an opportunity to engineer biologics, with the goal of increasing the humanness of the therapeutic protein.